• If you are wondering whether Guardant Health at around US$133 is starting to look stretched or still offers value, this article walks through the key signals that may matter to you as a shareholder or potential buyer.
• The stock has logged returns of 12.9% over the past week, 60.3% over the past month, 30.9% year to date and 245.6% over the past year. This puts recent pricing firmly in focus for any valuation check.
• Recent coverage has highlighted Guardant Health as a high growth healthcare stock, which helps explain why sentiment and prices have been so active lately. Longer term return figures of 324.4% over three years and 13.0% over five years also keep performance firmly on investors' radars.
• Even with that backdrop, Guardant Health scores only 2 out of 6 on Simply Wall St's valuation checks. Next you will see how different valuation approaches line up for this stock and why a broader view of value sits at the end of the article.

Guardant Health scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Guardant Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model looks at the cash Guardant Health is expected to generate in the future and then discounts those cash flows back to what they could be worth in today's dollars.

For Guardant Health, the latest twelve month free cash flow is a loss of $232.5 million. Analysts have provided forecasts out to 2030, and Simply Wall St then extrapolates further to build a 2 stage Free Cash Flow to Equity model. In this view, free cash flow is projected to be $560.2 million in 2030, with later years rising into the low billions of dollars based on the extrapolated path.

Using these projections, the DCF model arrives at an estimated intrinsic value of $209.53 per share. Against a current share price of about $133, this implies the stock trades at a 36.4% discount to that estimate, which indicates Guardant Health appears undervalued on this cash flow based approach.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Guardant Health is undervalued by 36.4%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Guardant Health Price vs Sales

For companies that are not yet consistently profitable, the P/S ratio is often more useful than P/E because it compares the stock price with revenue rather than earnings, which can still be negative during heavy investment phases.

Investors usually expect higher growth and higher risk to show up as a higher P/S ratio, while slower growth or lower risk can line up with a lower P/S that sits closer to the broader Healthcare industry. What matters is how the current multiple stacks up against what the business profile might justify.

Guardant Health currently trades on a P/S of 16.35x. That stands well above the Healthcare industry average P/S of 1.22x and also above the peer group average of 1.32x. Simply Wall St’s Fair Ratio of 6.02x is a proprietary estimate of what Guardant Health’s P/S could be, given factors like earnings growth expectations, industry, profit margin, market cap and specific risks.

This Fair Ratio aims to be more tailored than a simple comparison with peers or an industry average because it adjusts for company specific drivers rather than treating all Healthcare stocks as equal. With a current P/S of 16.35x versus a Fair Ratio of 6.02x, Guardant Health appears expensive on this sales-based check.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 21 top founder-led companies.

Upgrade Your Decision Making: Choose your Guardant Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced as a simple way for you to attach a clear story about Guardant Health to the numbers you care about, linking your view of its future revenue, earnings and margins to a forecast and then to a fair value that you can compare with the current share price.

On Simply Wall St's Community page, Narratives are available as an easy tool that lets you see and adjust these stories, and they update automatically when new information such as earnings, clinical data or reimbursement news appears so your view does not stay static.

For Guardant Health, one investor might build a Narrative that looks closer to the more bullish fair value of about US$140.00, based on assumptions like 36.0% annual revenue growth and earnings of US$123.6 million by 2028. Another might lean toward a more cautious Narrative nearer US$82.18, using assumptions like 24.6% annual revenue growth and earnings of US$95.2 million by 2029. Comparing each fair value with today’s price helps you decide whether the stock fits your own expectations.

For Guardant Health, we will make it really easy for you with previews of two leading Guardant Health narratives:

Fair value in this bullish narrative: US$140.00 per share.

Gap to that fair value at the last close of US$133.22: about 4.8% below the narrative fair value.

Revenue growth assumption: 35.95% a year.

• Expects Shield screening, Guardant360 Smart, Reveal MRD and data partnerships to support strong multi year test volume and revenue growth across oncology and screening.
• Assumes profit margins gradually move toward the wider US Healthcare industry level, with earnings reaching about US$123.6 million by 2028 and a high future P/E multiple applied to those earnings.
• Highlights several execution and reimbursement risks around Shield pricing, MRD coverage, competition and large scale evidence generation that could challenge the optimistic path if outcomes or timing differ from expectations.

Fair value in this more cautious narrative: about US$128.33 per share.

Gap to that fair value at the last close of US$133.22: about 3.8% above the narrative fair value.

Revenue growth assumption: 28.05% a year.

• Frames Guardant Health as benefiting from rising use of blood based cancer diagnostics and AI supported analytics, with revenue and margin potential tied to broader adoption of Guardant360, Reveal and Shield.
• Builds in higher spending, ongoing losses and substantial cash burn, with future earnings and valuation relying on reimbursement progress, payer adoption and supportive guideline decisions over several years.
• Points to competition, reimbursement and macro pressures as key factors that could limit revenue growth, delay profitability or lead to dilution, even if analyst price targets currently sit above the last close.

If you want to go further than these snapshots and see how your own expectations compare, you can review the full set of community viewpoints including both optimistic and cautious cases in one place, then decide which story comes closest to how you see Guardant Health. See what the community is saying about Guardant Health

Do you think there's more to the story for Guardant Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.